2018
DOI: 10.3324/haematol.2017.182352
|View full text |Cite
|
Sign up to set email alerts
|

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(11 citation statements)
references
References 13 publications
1
10
0
Order By: Relevance
“…Likewise, exposure‐response analyses of trastuzumab treatment in patients with HER2+ cancers have suggested that patients with low drug exposures had shorter overall survival times; however, increasing the dose did not lead to an improvement in efficacy . Similar results have been found in CLL and DLBCL patients treated with dose dense treatment regimens of rituximab . Recently, a Food and Drug Administration pharmacometric reviewer highlighted the complexity of such analyses: “When both the response and the drug target can affect the exposure, the causal relationship between the two becomes confounded.…”
Section: Discussionmentioning
confidence: 58%
“…Likewise, exposure‐response analyses of trastuzumab treatment in patients with HER2+ cancers have suggested that patients with low drug exposures had shorter overall survival times; however, increasing the dose did not lead to an improvement in efficacy . Similar results have been found in CLL and DLBCL patients treated with dose dense treatment regimens of rituximab . Recently, a Food and Drug Administration pharmacometric reviewer highlighted the complexity of such analyses: “When both the response and the drug target can affect the exposure, the causal relationship between the two becomes confounded.…”
Section: Discussionmentioning
confidence: 58%
“…The 62% efficacy rate was high, especially since calculated by ITT (85 of all 135 patients enrolled), and more than double that typically reported for six cycles of FCR (under 30%); the primary objective was thus exceeded by far. [3][4][5][6]8 The rate is superior to that reported for any first-line regimen based on chemotherapy plus rituximab. [3][4][5][6][7]8,25 A feature of our experimental strategy is that patients received study treatment for a definite period of time (total 15 months).…”
Section: Discussionmentioning
confidence: 82%
“…[3][4][5][6]8 The rate is superior to that reported for any first-line regimen based on chemotherapy plus rituximab. [3][4][5][6][7]8,25 A feature of our experimental strategy is that patients received study treatment for a definite period of time (total 15 months).…”
Section: Discussionmentioning
confidence: 82%
See 2 more Smart Citations